In this case study, Frontage successfully completes the method development and validation under the Sponsor's pressing timelines, while providing high quality, and reproducible data with an ISR passing rate of over 90%.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
To ensure good data yield, there are challenges encountered during NGS operations, especially with poor quality RNA or DNA material, which is a common scenario for clinical samples. In this poster, we showcase three key tricks during the NGS operations to generate consistent data with high quality.
In this poster, we validate ultra-high sensitive SIMOA assays for the successful quantitation of neurofilament light chain (NF-L) and glial fibrillary acidic protein (GFAP).
The diagnosis and treatment of human diseases and the development of new drugs increasingly rely on our ability to determine patient genotypes using accurate and sensitive pharmacogenomic tests. Many PCR and next-generation sequencing (NGS) based assay platforms are currently available.
However, the type of DNA sequence variants, the number of targets, and the sensitivity requirements are highly diverse in different studies. Here Dr. Peter Zhang describes the design, performance, and regulatory considerations of several assay platforms that are accurate, high throughput, cost-effective and customizable. These platforms provide high-quality pharmacogenomic data ideally suited to meet the needs of individual studies.